Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Renalytix plc (RNLX) to participate in BTIG MedTech Conference in Snowbird, Utah without a formal presentation.
02/09/2024 - 09:00 AM
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
About Renalytix www.renalytix.com .
For further information, please contact:
Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker) Tel: 020 7597 4000 Gary Clarence / Shalin Bhamra Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654 CapComm Partners Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com
Renalytix plc will participate in the BTIG MedTech Conference on February 13-14, 2024.
The BTIG MedTech Conference will take place in Snowbird, Utah.
Renalytix plc will be participating in one-on-one meetings with investors during the event.
RNLX Rankings
#4481 Ranked by Stock Gains
RNLX Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Technology Services, Packaged Software, Health Care and Social Assistance, Diagnostic Imaging Centers
Country
United Kingdom
City
Penarth
About RNLX
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev
